Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Liothyronine sodium/Thiamazole Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Liothyronine sodium/Thiamazole: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Curcumin C3 complex Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Curcumin C3 complex: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SAR-446523 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
SAR-446523: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PBF-677 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
PBF-677: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PRS-342 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
PRS-342: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HTL-0039732 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
HTL-0039732: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IVS-3001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
IVS-3001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AB-1009 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
AB-1009: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TT-702 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
TT-702: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CLYM116 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CLYM116: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SOT-109 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
SOT-109: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vepafestinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Vepafestinib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.